Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Lundbeck's Vyepti Launch In US Disappoints In First Half

The coronavirus pandemic held back sales of Lundbeck’s newest product, Vyepti, in the US during the first half, but the company spent less than expected on SG&A because of COVID-19, and increased investments in marketing infrastructure and restructuring R&D.

Sales & Earnings Coronavirus COVID-19 Commercial

The Top 10 Best-Selling Drugs of 2019

INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market. 

Commercial Companies Sales & Earnings

Fresh Twist: India Stays Revocation Order On Novartis Ceritinib Patent

Appellate board stays previous order that rescinded the patent on ceritinib in India, giving Novartis the upper hand for now. The spotlight is now on procedural aspects and additional evidence/submission by challenger Natco and rebuttal by the Swiss multinational.

Companies Intellectual Property India

Coronavirus Spotlight

Russia Approves First COVID-19 Vaccine

The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October. 

 

Coronavirus COVID-19 Approvals

Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.


Recent Tweets from Scrip


Coronavirus 2019-nCov novel coronavirus concept resposible for asian flu outbreak and coronaviruses influenza as dangerous flu strain cases as a pandemic 3d rendering

COVID-19 Pipeline Tracker

Product candidates in development worldwide to address the 2019-nCoV pandemic, categorized by treatment and prevention. Subscription required.

View Tracker

 

Infographics

The Top 10 Best-Selling Drugs of 2019

INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market. 

COVID-19: The Race To Develop A Vaccine

The world is waiting for a coronavirus vaccine – but can we depend on it, and when will it arrive? A visual tracker of key developments from leading candidates.

The 2020 Worldwide Pharma & Biotech Industry R&D Scene

INFOGRAPHIC: A snapshot of the industry in key performance indicators, taken in early 2020.

Commercial Explore this Topic

Set Alert for Commercial

Scipher Hopes IBD Alliance With Galapagos Is The First Of Many

Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.

Deals Business Strategies

Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients

Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.

Business Strategies Deals

Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers

Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.

Deals Cancer

Strides Hits Pause On Investments In Stelis’s Injectables

Strides has paused further investments in the sterile injectables business under Stelis, citing pandemic-related uncertainty and loss of revenue from ranitidine withdrawal in the US. A prior investment commitment of $40m in Stelis will, however, be fulfilled. Meanwhile, Strides reported a strong first quarter led by non-US markets.

Commercial Sales & Earnings

Cellular Biomedicine To Go Private In Consortium Buyout

Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.

Deals M & A

Finance Watch: 2020 Cell And Gene Therapy Funding Already Bests 2019

Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.

Financing Innovation
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Russia Approves First COVID-19 Vaccine

The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October. 

Coronavirus COVID-19 Approvals

Q&A: BIO CEO Michelle McMurry-Heath Outlines Diversity Goals

Expanding on difficult conversations during the recent BIO Digital meeting, the group aims to take actions that will increase diversity and inclusion in health care, science and industry.

Clinical Trials Human Capital

Roche’s Evrysdi Approved For SMA, Priced Below Competitors

Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma. 

Approvals Launches
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers

Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.

Deals Cancer

Coronavirus Update: Cheaper Remdesivir Available In India

A new cheaper version of antiviral remdesivir has been launched locally by a Indian licensee, while Chinese vaccine developers push forward with broader trials of their candidates.

Coronavirus COVID-19 Clinical Trials

Antifungal Specialist F2G Gets Near $61m Financing

A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.

Financing Companies
See All
UsernamePublicRestriction

Register